WO2004100889A2 - Compositions cosmetiques et procedes d'utilisation de celles-ci pour ameliorer l'apparence esthetique de la peau - Google Patents

Compositions cosmetiques et procedes d'utilisation de celles-ci pour ameliorer l'apparence esthetique de la peau Download PDF

Info

Publication number
WO2004100889A2
WO2004100889A2 PCT/US2004/014468 US2004014468W WO2004100889A2 WO 2004100889 A2 WO2004100889 A2 WO 2004100889A2 US 2004014468 W US2004014468 W US 2004014468W WO 2004100889 A2 WO2004100889 A2 WO 2004100889A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
improvement
aging
acid
reduction
Prior art date
Application number
PCT/US2004/014468
Other languages
English (en)
Other versions
WO2004100889A3 (fr
Inventor
Harish Mahalingam
Christos D. Kyrou
Michael Traudt
Dmitri Ptchelintsev
Original Assignee
Avon Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products, Inc. filed Critical Avon Products, Inc.
Priority to JP2005518232A priority Critical patent/JP2006514997A/ja
Priority to PL04760943T priority patent/PL1622579T3/pl
Priority to MXPA04008328 priority patent/MX282977B/es
Priority to CA2477748A priority patent/CA2477748C/fr
Priority to EP04760943A priority patent/EP1622579B1/fr
Priority to AT04760943T priority patent/ATE503454T1/de
Priority to DE602004032018T priority patent/DE602004032018D1/de
Priority to AU2004238316A priority patent/AU2004238316B9/en
Priority to BRPI0403036-2A priority patent/BRPI0403036B1/pt
Publication of WO2004100889A2 publication Critical patent/WO2004100889A2/fr
Publication of WO2004100889A3 publication Critical patent/WO2004100889A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to compositions useful in treating hyperpigmentation and the various signs of dermatological aging in human skin.
  • the present invention also relates to cosmetic compositions and methods of using such compositions that improve the aesthetic appearance of skin.
  • the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin.
  • Human skin color is determined primarily by the content of the pigment melanin in the basal epidermis layer.
  • Melanin is synthesized by the process of melanogenesis within elanocytes (pigment-producing cells). Melanin is deposited onto melanosomes, which are transferred to keratinocytes in the basal epidermal layer. Melanosomes present in these basal keratinocytes are the key determinants of skin color.
  • the keratinocytes leave the basal layer and undergo differentiation forming the cornified top layer of the skin. Once the keratinocytes leave the basal layer, the melanosomes lose their characteristic electron dense structure, and the load of melanin is carried to the surface of the skin by the differentiating keratinocytes.
  • the skin can become hyperpigmented when too much melanin concentrates at one area or portion of the skin due to the retention time of the melanosomes in the basal layer. Hyperpigmentation can also occur as a result of overexposure
  • Hyperpigmentation can take the form of solar lentigines (age spots), ephilides (freckles), melasma, chloasma, and pigmented keratoses.
  • the prior art discloses ways to treat hyperpigmentation by application of skin lightening agents.
  • Representative skin lightening agents include hydroquinone and Vitamin C. Such agents typically lighten the skin by inhibiting the expression of tyrosinase enzymes involved in melanogenesis.
  • a reduction in ability to retain melanin would speed the transfer of the melasonomes to the keratinocytes and allow existing hyperpigmented portions of the skin to be lightened or de-pigmented faster than with conventional skin lightening agents, which act primarily to inhibit the formation of new melanin.
  • Such anti-aging active ingredients include, for example, a-hydroxy acids (e.g., lactic, glycolic, citric), b-hydroxy acids (e.g., salicylic; 5-n-octanoylsalicylic acids) and retinoids (retinoic acids; retinol). It is known that these anti-aging active ingredients have a significant disadvantage in that they frequently are associated with consumer discomfort characterized by burning, smarting, itching or sensation of tightness after application. There remains a general need in the cosmetics industry for products that retard or counter aging effects on the skin, and more specifically for products that produce such effects without undesirable side effects!
  • a-hydroxy acids e.g., lactic, glycolic, citric
  • b-hydroxy acids e.g., salicylic; 5-n-octanoylsalicylic acids
  • retinoids retinoic acids
  • a method and composition that comprises (a) a de-pigmenting agent or anti-aging agent in an amount effective to prevent, treat and/or ameliorate pigmentation or the various signs of aging at an area of skin to which it is applied, and (b) a cosmetically or pharmaceutically acceptable vehicle.
  • Suitable de-pigmenting agents include 3,3'- thiodipropionic acid, thiazolidine-2-carboxylic acid, Kaempferol-7-glucoside, perilla oil, and clofibrate and clofibrate analogs and/or derivatives, as well as those set forth below.
  • Suitable anti-aging agents include 3,3'-thiodipropionic acid and/or its derivatives.
  • the present invention provides for de-pigmenting compositions containing an effective amount of one or more depigmenting agents which, when applied to human skin, prevent, treat and/or ameliorate pigmentation at the area or portion of skin to which they are applied.
  • the compositions are effective at reducing or diminishing pigmented areas or portions of the skin such as age spots, freckles, melasma, chloasma, and pigmented keratoses.
  • the compositions are topically applied to the skin.
  • the present invention also provides for anti-aging compositions containing an effective amount of one or more ingredients which, when applied to human skin, prevent, treat and/or ameliorate the various signs of aging at the area or portion of skin to which they are applied.
  • the present invention provides anti-aging benefits to and improves the aesthetic appearance of the skin.
  • the present invention provides compositions and methods for treating skin to prevent, inhibit, reduce and/or ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • Such signs of aging include, but are not limited to skin fragility; loss of collagen and/or elastin; estrogen imbalance in skin; skin atrophy; appearance and/or depth of lines and/or wrinkles, including fine lines; skin discoloration, including dark eye circles; skin sagging; skin fatigue and/or stress, e.g. skin breakout due to environmental stress, such as pollution and/or temperature changes; skin dryness; skin flakiness; cellular aging; loss of skin tone, elasticity and/or luster; loss of skin firmness; poor skin texture; loss of skin elasticity and/or resiliency; and thin skin.
  • the benefits and improvements to the aesthetic appearance of skin can be manifested in any of the following: reduction in pore size; improvement in skin tone, radiance, clarity and/or tautness; promotion of anti-oxidant activity; improvement in skin firmness, plumpness, suppleness, and/or softness; improvement in procollagen and/or collagen production; improvement in skin texture and/or promotion of retexturization; improvement in skin barrier repair and/or function; improvement in appearance of skin contours; restoration of skin luster and/or brightness; replenishment of essential nutrients and/or constituents in the skin decreased by aging and/or menopause; improvement in communication among skin cells; increase in cell proliferation and/or multiplication; increase in skin cell metabolism decreased by aging and/or menopause; improvement in skin moisturization; promotion and/or acceleration of cell turnover; enhancement of skin thickness; increase in skin elasticity and/or resiliency; and enhancement of exfoliation, with or without the use of alpha or beta hydroxy acids, keto acids or other exfoliants.
  • a first embodiment of the present composition has a compound corresponding to the following Formula (I):
  • R-i and R 2 are independently selected from the group of substituents consisting of hydrogen; alkyls, substituted or unsubstituted, branched or linear; alkenyls, substituted or unsubstituted, branched or linear, and having up to 5 double bonds; alkynyls, substituted or unsubstituted, branched or linear and having up to 5 triple bonds; aryls, substituted or unsubstituted; cycloalkyls, substituted and unsubstituted; and cycloalkenyls, substituted and unsubstituted.
  • Formula I compounds shall be referred to herein as either "de-pigmenting agents" or "anti- aging agents”.
  • the Formula I compound is 3,3'-thiodipropionic acid, wherein Ri and R 2 are hydrogen.
  • a second embodiment of the present composition has a de-pigmenting agent corresponding to formula II: (II)
  • R 3 and R 4 are defined the same as R-i and R 2 in formula (I) above; in addition, R 3 can be an acyl group; wherein "n" is an integer from 1 to 4, preferably 1 to 3, and most preferably 1 to 2.
  • the de-pigmenting agent is perilla oil. Perilla oil is derived from the seeds of the mint of the genus Per/7/a.
  • the de-pigmenting agent is clofibrate or a clofibrate analog or derivative.
  • Clofibrate is ethyl 2-(p- chlorophenoxy)isobutyrate, which corresponds to the following formula (IV):
  • a fifth embodiment of the present composition has a de-pigmenting agent corresponding to the following formula (III):
  • the de-pigmenting agent of Formula III is kaempferol-7-glycoside wherein R 5 , Re and R 7 are hydrogen. Kaempferol-7-glycoside is believed to reduce pigmentation by inhibiting tyrosinase but may also reduce pigmentation by alternate pathways.
  • the de-pigmenting agent is a combination of one or more of the above de-pigmenting agents.
  • the combination includes de-pigmenting agents that utilize different mechanisms of action.
  • a preferred combination includes kaempferol-7-glucoside and perilla oil or clofibrate (or a clofibrate analog or derivative).
  • the de-pigmenting agent is present in the composition at an amount effect to prevent, treat, or ameliorate pigmentation at the area or portion of skin to which it is applied.
  • the de-pigmenting agent is preferably present at about 0.0001 percentage by weight (wt%) to about 98 wt%, more preferably at about 0.001 wt% to about 30 wt%, and most preferably at about 0.05 wt% to about 10 wt% based on the total weight of the composition.
  • the composition is preferably applied to an affective area of skin for a period of time prevent, treat, or ameliorate pigmentation of the area of skin to which the composition is applied.
  • the amount of times per day and the period of time that the composition is to be applied to be effective will vary according to the percentage of active used in the composition, the additional ingredients in the composition (e.g., whether or not there is a penetration enhancer or additional depigmenting agents), as well as other factors known by those skilled in the art.
  • the anti-aging agent is present in the composition at an amount effect to prevent, treat, or ameliorate the various signs of aging in the area or portion of skin to which it is applied.
  • the anti-aging agent is preferably present at about 0.0001 percentage by weight (wt%) to about 98 wt%, more preferably at about 0.001 wt% to about 30 wt%, and most preferably at about 0.05 wt% to about 10 wt% based on the total weight of the composition.
  • the composition is preferably applied to an affective area of skin for a period of time to improve the aesthetic appearance of the area of skin to which the composition is applied.
  • the amount of times per day and the period of time that the composition is to be applied to be effective will vary according to the percentage of active used in the composition, the additional ingredients in the composition (e.g., whether or not there is a penetration enhancer or additional anti-agents), the targeted improvement as well as other factors known by those skilled in the art.
  • the present invention provides compositions and methods for treating skin to prevent, inhibit, reduce and/or ameliorate the signs of dermatological aging due to, for example, chronological aging, hormonal aging, and/or photoaging.
  • signs of aging include, but are not limited to skin fragility; loss of collagen and/or elastin; estrogen imbalance in skin; skin atrophy; appearance and/or depth of lines and/or wrinkles, including fine lines; skin discoloration, including dark eye circles; skin sagging; skin fatigue and/or stress, e.g.
  • the benefits and improvements to the aesthetic appearance of skin can be manifested in any of the following: reduction in pore size; improvement in skin tone, radiance, clarity and/or tautness; promotion of anti-oxidant activity; improvement in skin firmness, plumpness, suppleness, and/or softness; improvement in procollagen and/or collagen production; improvement in skin texture and/or promotion of retexturization; improvement in skin barrier repair and/or function; improvement in appearance of skin contours; restoration of skin luster and/or brightness; replenishment of essential nutrients and/or constituents in the skin decreased by aging and/or menopause; improvement in communication among skin cells; increase in cell proliferation and/or multiplication; increase in skin cell metabolism decreased by aging and/or menopause; improvement in skin moisturization; promotion and/or acceleration of cell turnover; enhancement of skin thickness; increase in skin elasticity and/or resiliency; and enhancement of exfoliation, with or without the use of alpha or beta hydroxy acids, keto acids or other exfoliants.
  • compositions on are preferably used in methods of improving, ameliorating or treating the following signs of aging skin: texture, clarity, pigmentation (mottled and/or discrete), fine wrinkles, coarse wrinkles, sallowness, laxness, sagging, turgor, undereye puffiness, and/or overall photodamage.
  • the Formula I compound is 3,3'-thiodipropionic acid and/or a derivative thereof. Most preferably, the Formula I compound is 3,3'-thiodipropionic acid.
  • compositions of the present invention comprise a pharmaceutically and/or cosmetically acceptable vehicle to provide bulk and physical form.
  • vehicle is hypoallergenic, as allergens and other irritating agents exacerbate pigmentation.
  • Suitable vehicles include, but are not limited to, cetyl alcohol, ethanol, glycerin, myristyl palmitate, polyvinyl alcohol, propylene glycol, propanol, and water, and mixtures thereof.
  • the depigmenting/anti-aging agent is admixed with the vehicle(s) along with any other adjuvants or ingredients to form the topical
  • compositions of the present invention may also include actives in the form of liposomes.
  • the present composition may take any suitable form such as a solution, cream, serum, stick, patch, mask, towelette, lotion, emulsion, ointment or gel.
  • the present composition may optionally have one or more of the following ingredients: anesthetics, antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • anesthetics antiallergenics, antimicrobial agents, antiseptics, chelating agents, colorants, demulcents, emollients, emulsifiers, exfolients, fragrances, humectants, lubricants, moisturizers, preservatives, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, and mixtures thereof.
  • the present invention may also include conventional cosmetic acitive agents, such as other conventional hypopigmenting agents, such as hydroquinone, ascorbic acid (Vitamin C) and/or licorice extract; retinoids, such as retinol or retinoic acid; anti- inflammatory agents, such as bisabolol, anti-acne agents, such as salicylic acid; exfoliants, such as alpha-hydroxy acids, beta-hydroxy acids, keto acids, oxa acids or oxa diacids (disclosed in U.S. Patent Nos. 5,847,003 and 5,834,513); ascorbyl- phosphoryl-cholesterol (disclosed in U.S. Patent No.
  • sunscreens such as oxybenzone, octyl methoxycinnamate, octyl salicylate, octocrylene, titanium dioxide, zinc oxide, butyl methoxydibenzoylmethane, methylene bis- benzotriazoylteramehtylbuthylphenol (MBBT), bis-ethylhexyl oxyphenol methoxyphenol triazine (BEMT); or anti-aging agents; or any combination thereof.
  • MBT methylene bis- benzotriazoylteramehtylbuthylphenol
  • BEMT bis-ethylhexyl oxyphenol methoxyphenol triazine
  • anti-aging agents or any combination thereof.
  • Preferred alpha-hydroxy acids include lactic acid, glycolic acid, or a mixture thereof.
  • the preferred oxa diacid is 3,6,9-trioxaundecanedioic acid.
  • Formula I compounds may be used to enhance the effectiveness of other skin care actives, such as those disclosed above and those skin care actives disclosed in U.S. Patent No. 6,492,326 at col. 5, lines 9 through col. 20, line 50, which is incorporated herein by reference.
  • De-pigmenting agent or anti-aging agent e.g. (3,3'-thiodipropionic acid) 0.001 to 98 pH adjusting agent (e.g. ammonium 0.001 to 4 Humectants (e.g. glycols, glycerols) 0.5 to 15
  • pH adjusting agent e.g. ammonium 0.001 to 4
  • Humectants e.g. glycols, glycerols
  • Thickeners e.g. gums, starches polymers 0.1 to 4
  • Chelating Agents e.g. EDTA 0.001 to 0.5
  • Emollients e.g. isopropyl myristate, fatty esters 1 to 10
  • Silicones cyclomethicone-pentamer 0.1 to 15 Preservative (e.g. parabens) 0.01 to 2
  • Alcohols e.g. ethanol 0 to 10
  • Antioxidants e.g. vitamin E acetate 0.01 to 5
  • Anti-inflammatory e.g. bisabolol
  • Sunscreen e.g. titanium dioxide/benzophenone-3, Butyl methoxydibenzoylmethane 0.01 to 15
  • the preferred anti-aging agent is 3,3'-thiodi ⁇ ropionic acid.
  • the cosmetic composition includes at least one ingredient selected from the group consisting of: palmatoyl tetrapeptide-3 (available under the trade name RIGIN from Sederma, France), Gymnostemma pentaphyllum and/or an extract therefrom, Stenolama chusana and/or an extract therefrom, Morinda citrifolia and/or an extract therefrom, Butea frondosa and/or an extract therefrom, Luteoline 7-beta-glucoside, ChlorosalicylicAcid, Naringi crenulata and/or an extract therefrom, Methylthioadenosine, Ferutinin, llex purpurea and/

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des compositions cosmétiques et des procédés d'utilisation desdites compositions destinées à améliorées l'apparence esthétique de la peau. La présente invention concerne également des procédés d'application desdites compositions sur la peau afin d'améliorer l'apparence esthétique de la peau, en particulier en luttant contre le vieillissement de la peau. Les objectifs de la présente invention sont atteints grâce à un procédé et à une composition contenant (a) un agent anti-vieillissement en quantité efficace pour prévenir, traiter, réduire, et/ou améliorer les signes divers du vieillissement sur une partie de la peau sur laquelle elle est appliquée, et (b) un excipient acceptable d'un point de vue cosmétique ou pharmaceutique. Les agents anti-vieillissement adaptés contiennent un acide thiodipropionique 3,3' et/ou ses dérivés.
PCT/US2004/014468 2003-05-12 2004-05-07 Compositions cosmetiques et procedes d'utilisation de celles-ci pour ameliorer l'apparence esthetique de la peau WO2004100889A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2005518232A JP2006514997A (ja) 2003-05-12 2004-05-07 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法
PL04760943T PL1622579T3 (pl) 2003-05-12 2004-05-07 Kompozycje kosmetyczne i sposoby ich zastosowania do polepszania wyglądu estetycznego skóry
MXPA04008328 MX282977B (es) 2003-05-12 2004-05-07 Composiciones cosmeticas y metodos para usarlas para mejorar el aspecto estetico de la piel.
CA2477748A CA2477748C (fr) 2003-05-12 2004-05-07 Compositions cosmetiques et methodes d'utilisation de celles-ci pour ameliorer l'esthetique de la peau
EP04760943A EP1622579B1 (fr) 2003-05-12 2004-05-07 Compositions cosmetiques et procedes d'utilisation de celles-ci pour ameliorer l'apparence esthetique de la peau
AT04760943T ATE503454T1 (de) 2003-05-12 2004-05-07 Kosmetische zusammensetzungen und verfahren zu ihrer verwendung zur verbesserung des ästhetischen erscheinungsbilds der haut
DE602004032018T DE602004032018D1 (de) 2003-05-12 2004-05-07 Kosmetische zusammensetzungen und verfahren zu ihrscheinungsbilds der haut
AU2004238316A AU2004238316B9 (en) 2003-05-12 2004-05-07 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
BRPI0403036-2A BRPI0403036B1 (pt) 2003-05-12 2004-05-07 "método cosmético para melhorar os sinais de envelhecimento da pele"

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/436,310 2003-05-12
US10/436,310 US20040067245A1 (en) 2000-12-20 2003-05-12 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin

Publications (2)

Publication Number Publication Date
WO2004100889A2 true WO2004100889A2 (fr) 2004-11-25
WO2004100889A3 WO2004100889A3 (fr) 2005-03-24

Family

ID=33449708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014468 WO2004100889A2 (fr) 2003-05-12 2004-05-07 Compositions cosmetiques et procedes d'utilisation de celles-ci pour ameliorer l'apparence esthetique de la peau

Country Status (13)

Country Link
US (3) US20040067245A1 (fr)
EP (2) EP2409681A1 (fr)
JP (2) JP2006514997A (fr)
CN (1) CN1697645A (fr)
AT (1) ATE503454T1 (fr)
AU (1) AU2004238316B9 (fr)
BR (1) BRPI0403036B1 (fr)
CA (1) CA2477748C (fr)
DE (1) DE602004032018D1 (fr)
MX (1) MX282977B (fr)
PL (1) PL1622579T3 (fr)
TW (1) TWI280139B (fr)
WO (1) WO2004100889A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1902756A1 (fr) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Composition et procédé pour traitement de la peau par Silybin et Pipérine/Tetrahydropipérine
EP1902755A1 (fr) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Composition cosmétique pour reduire la liberation de GM-CSF par des sels du nickel
JP2008525462A (ja) * 2004-12-22 2008-07-17 エイボン プロダクツ インコーポレーテッド しわの外観を減少させるための方法および組成物
WO2008151890A1 (fr) * 2007-06-11 2008-12-18 Chanel Parfums Beaute Utilisation d'agents actifs pour stimuler l'expression de la fn3k et/ou d'une protéine associée à la fn3k pour combattre le vieillissement de la peau
WO2008151891A1 (fr) * 2007-06-11 2008-12-18 Chanel Parfums Beaute Utilisation cosmétique d'agents actifs pour stimuler l'expression de fn3k et d'une protéine associée à la fn3k afin d'améliorer la fonction barrière de la peau
WO2009047150A2 (fr) * 2007-10-09 2009-04-16 Basf Se Produits de soin du corps et ménagers et compositions comprenant des composés spécifiques contenant du soufre
JP2009280549A (ja) * 2008-05-26 2009-12-03 Tahitian Noni Internatl Inc エラスターゼ阻害剤
EP2384195A1 (fr) * 2008-12-29 2011-11-09 Avon Products, Inc. Applications cosmétiques des 1-aroyl-n-(2-oxo-3-pipéridinyl)-2-pipérazinecarboxamides et des composés apparentés
US8426149B2 (en) 2007-10-01 2013-04-23 The University Of British Columbia Granzyme A and granzyme B diagnostics
US9060960B2 (en) 2007-10-01 2015-06-23 The University Of British Columbia Treatment of dissection, aneurysm, and atherosclerosis using granzyme B inhibitors
US9579279B2 (en) 2010-04-22 2017-02-28 Skinergistics Clinical Skin Solutions Inc. Seaweed-derived cosmetic compositions

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176658D1 (en) * 1981-12-10 1988-03-31 Revlon Process for making metallic leafing pigments
US7189419B2 (en) * 2002-12-17 2007-03-13 Avon Products, Inc. Use of active extracts to lighten skin, lips, hair, and/or nails
US20050136028A1 (en) * 2003-12-19 2005-06-23 Dmitri Ptchelintsev Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
JP4673851B2 (ja) * 2004-08-30 2011-04-20 花王株式会社 脂肪分解促進剤及び痩身用皮膚外用組成物
FR2902324B1 (fr) * 2006-06-20 2009-04-03 Oreal Utilisation d'acide ellagique pour le traitement de la canitie
WO2008018133A1 (fr) * 2006-08-10 2008-02-14 Noevir Co., Ltd. Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau
MX368365B (es) * 2009-12-22 2019-09-30 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
EP2588593B1 (fr) * 2010-06-30 2017-08-23 Avon Products, Inc. Compositions et procédés de stimulation de magp-1 pour améliorer l'aspect de la peau
CN111700838A (zh) * 2012-04-20 2020-09-25 宝洁公司 用于改善面部毛孔外观的组合物和方法
WO2014035401A1 (fr) * 2012-08-30 2014-03-06 Avon Products, Inc. Compositions modulant l'expression dickkopf-1 et leurs utilisations
US9023327B2 (en) 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof
CA2899426C (fr) * 2013-03-07 2021-05-18 Avon Products, Inc. Utilisation d'un acide thio-3,3'dipropionique et derives connexes pour reparer les cheveux endommages
CN105102073B (zh) * 2013-03-12 2019-06-04 雅芳产品公司 局部用增亮组合物及其使用方法
KR102020817B1 (ko) * 2013-08-14 2019-09-11 주식회사 엘지생활건강 피부 재생, 주름개선, 항산화 및 항염증용 조성물
CN111032203B (zh) * 2017-04-03 2022-11-15 欧莱雅 用于形成美容组合物的系统及皮肤护理管理系统
KR102362617B1 (ko) * 2018-05-16 2022-02-11 오오타 유시 가부시키가이샤 피부의 광노화 예방제, 및, 이것을 함유하는 기능성 화장품
CN110200883A (zh) * 2019-06-19 2019-09-06 武汉百思凯瑞生物科技有限公司 一种抗敏共输送纳米组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686489A (en) * 1986-12-23 1997-11-11 Tristrata Technology, Inc. Alpha hydroxyacid esters for skin aging
BE1000724A6 (fr) * 1987-05-20 1989-03-21 Stiefel Lab Ltd Compositions a base de dithranol.
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
CH686285A5 (fr) * 1992-08-06 1996-02-29 Beiersdorf Ag Preparation cosmetique ou pharmaceutique servant a retarder le vieillissement de la peau humaine.
DE4305788C2 (de) * 1993-02-25 1997-06-12 Beiersdorf Ag Kosmetische und dermatologische Formulierungen zum Schutze der Haut gegen Oxidationsprozesse
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US5866147A (en) 1995-05-15 1999-02-02 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
FR2742750B1 (fr) * 1995-12-22 1998-01-30 Oreal Nouveaux derives de l'acide l-2-oxothiazolidine 4-carboxylique et leur utilisation pour le soin de la peau
US5834513A (en) * 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions
US5847003A (en) 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6068848A (en) * 1997-12-17 2000-05-30 Color Access, Inc. Antioxidant mixture comprising tocopherol
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
DE19929511C2 (de) * 1999-06-29 2003-04-10 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Aniontensidmischungen
CA2413919A1 (fr) * 2000-03-21 2001-09-13 Avon Products, Inc. Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes
FR2807323A1 (fr) * 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
JP3636973B2 (ja) * 2000-06-26 2005-04-06 株式会社カネボウ化粧品 ラジカル消去剤および化粧料
US6562321B2 (en) * 2000-12-20 2003-05-13 Avon Products, Inc. Compositions and methods for treating hyperpigmentation
US6500857B1 (en) * 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
DE10132338A1 (de) * 2001-07-04 2003-01-16 Basf Ag Verwendung von 5'-Desoxy-5'-methylthioadenosin in hautkosmetischen Mitteln
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP1622579A4

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525462A (ja) * 2004-12-22 2008-07-17 エイボン プロダクツ インコーポレーテッド しわの外観を減少させるための方法および組成物
US9149665B2 (en) 2004-12-22 2015-10-06 Avon Products, Inc. Method and composition for reducing appearance of wrinkles
EP1902756A1 (fr) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Composition et procédé pour traitement de la peau par Silybin et Pipérine/Tetrahydropipérine
EP1902755A1 (fr) * 2006-09-19 2008-03-26 Cognis IP Management GmbH Composition cosmétique pour reduire la liberation de GM-CSF par des sels du nickel
WO2008034535A1 (fr) * 2006-09-19 2008-03-27 Cognis Ip Management Gmbh Procédé servant à traiter la peau en administrant un agent qui diminue la libération du gmcsf des kératinocytes
WO2008151890A1 (fr) * 2007-06-11 2008-12-18 Chanel Parfums Beaute Utilisation d'agents actifs pour stimuler l'expression de la fn3k et/ou d'une protéine associée à la fn3k pour combattre le vieillissement de la peau
WO2008151891A1 (fr) * 2007-06-11 2008-12-18 Chanel Parfums Beaute Utilisation cosmétique d'agents actifs pour stimuler l'expression de fn3k et d'une protéine associée à la fn3k afin d'améliorer la fonction barrière de la peau
US8715948B2 (en) 2007-10-01 2014-05-06 The University Of British Columbia Granzyme A and granzyme B diagnostics
US8426149B2 (en) 2007-10-01 2013-04-23 The University Of British Columbia Granzyme A and granzyme B diagnostics
US9060960B2 (en) 2007-10-01 2015-06-23 The University Of British Columbia Treatment of dissection, aneurysm, and atherosclerosis using granzyme B inhibitors
US9176138B2 (en) 2007-10-01 2015-11-03 The University Of British Columbia Granzyme A and granzyme B diagnostics
WO2009047150A3 (fr) * 2007-10-09 2010-09-02 Basf Se Produits de soin du corps et ménagers et compositions comprenant des composés spécifiques contenant du soufre
WO2009047150A2 (fr) * 2007-10-09 2009-04-16 Basf Se Produits de soin du corps et ménagers et compositions comprenant des composés spécifiques contenant du soufre
JP2009280549A (ja) * 2008-05-26 2009-12-03 Tahitian Noni Internatl Inc エラスターゼ阻害剤
EP2384195A1 (fr) * 2008-12-29 2011-11-09 Avon Products, Inc. Applications cosmétiques des 1-aroyl-n-(2-oxo-3-pipéridinyl)-2-pipérazinecarboxamides et des composés apparentés
EP2384195A4 (fr) * 2008-12-29 2012-05-30 Avon Prod Inc Applications cosmétiques des 1-aroyl-n-(2-oxo-3-pipéridinyl)-2-pipérazinecarboxamides et des composés apparentés
US9579279B2 (en) 2010-04-22 2017-02-28 Skinergistics Clinical Skin Solutions Inc. Seaweed-derived cosmetic compositions
US10004681B2 (en) 2010-04-22 2018-06-26 Skinergistics Clinical Skin Solutions Inc. Seaweed-derived cosmetic compositions

Also Published As

Publication number Publication date
US20140308376A1 (en) 2014-10-16
US8808765B2 (en) 2014-08-19
EP2409681A1 (fr) 2012-01-25
EP1622579B1 (fr) 2011-03-30
TWI280139B (en) 2007-05-01
JP2006514997A (ja) 2006-05-18
US20040067245A1 (en) 2004-04-08
BRPI0403036A (pt) 2005-11-22
CN1697645A (zh) 2005-11-16
BRPI0403036B1 (pt) 2014-12-16
EP1622579A4 (fr) 2007-12-12
EP1622579A2 (fr) 2006-02-08
AU2004238316B2 (en) 2007-08-23
WO2004100889A3 (fr) 2005-03-24
DE602004032018D1 (de) 2011-05-12
PL1622579T3 (pl) 2011-08-31
ATE503454T1 (de) 2011-04-15
AU2004238316A1 (en) 2004-11-25
CA2477748C (fr) 2011-12-06
MX282977B (es) 2011-01-17
AU2004238316B9 (en) 2007-08-23
MXPA04008328A (es) 2005-02-03
JP2009046510A (ja) 2009-03-05
TW200505490A (en) 2005-02-16
CA2477748A1 (fr) 2004-11-12
US20120315344A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
US8808765B2 (en) Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US6562321B2 (en) Compositions and methods for treating hyperpigmentation
US20030118617A1 (en) Resveratrol analogues
WO2006068778A2 (fr) Utilisation d'extraits vegetaux pour la prevention et/ou la reduction de signes de malaise subjectif et/ou d'irritation dans l'application topique de produits cosmetiques
EP1536763B1 (fr) Composition de depigmentation pour la peau comprenant de l'adapalene et au moins un agent de depigmentation
US20070238764A1 (en) Use of Sphingoid Base Associated with Nicotinic Acid or a Nicotinic Acid Amide in the Form of Depigmentation Agent
US9592186B2 (en) Topical compositions and methods for skin lightening
US20030198657A1 (en) Methods using phytol to improve the appearance of skin and compositions for such methods
EP1261314A1 (fr) Methodes utilisant du phytol destinees a l'amelioration de l'apparence de la peau et compositions correspondantes
CN114288200A (zh) 皱纹改善剂
KR102623565B1 (ko) 베타피넨을 유효성분으로 포함하는 피부 개선용 조성물
US20230346678A1 (en) Topical compositions containing vitamin c
WO2016053284A1 (fr) Compositions topiques et méthodes d'éclaircissement de la peau
KR20150087138A (ko) 피부 개선용 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/008328

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2477748

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005518232

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20048001282

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004760943

Country of ref document: EP

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004238316

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004238316

Country of ref document: AU

ENP Entry into the national phase

Ref document number: PI0403036

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 2004760943

Country of ref document: EP